A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Konstantinos Tzelepis(Wellcome/MRC Cambridge Stem Cell Institute), Kosuke Yusa(Kyoto University), Malgorzata Gozdecka(Wellcome Sanger Institute), Paolo Gallipoli(Wellcome/MRC Cambridge Stem Cell Institute), Vera Grinkevich(Wellcome Sanger Institute), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Sarah A. Teichmann(Stem Cell Institute), Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), Shuhei Ohnishi(Wellcome Sanger Institute), Étienne De Braekeleer(Wellcome Sanger Institute), Hiroko Koike-Yusa(Wellcome Sanger Institute), Oliver M. Dovey(Wellcome Sanger Institute), Annalisa Mupo(Wellcome Sanger Institute), Cristina Pina(NHS Blood and Transplant), Ana Filipa Domingues(NHS Blood and Transplant), Milena Mazan(Wellcome Sanger Institute), Ultan McDermott(AstraZeneca (United Kingdom)), Emmanouil Metzakopian(Babraham Institute), Francesco Iorio(Human Technopole), Hannes Ponstingl(Wellcome Sanger Institute), Thomas McKerrell(Wellcome Sanger Institute), Bin Chen(Leshan Normal University), Yilong Li(Guizhou Academy of Agricultural Sciences), Jonathan Cooper(Wellcome Sanger Institute), Miten Patel(Wellcome Sanger Institute), Meng Li(Xi'an Technological University), Julio Sáez-Rodríguez(European Bioinformatics Institute)
Cited by 834
Related Papers
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k